Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.
about
Plasmodium vivax Controlled Human Malaria Infection - Progress and ProspectsRational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models.Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria TransmissionRationale for Further Development of a Vaccine Based on the Circumsporozoite Protein of Plasmodium vivaxManagement of relapsing Plasmodium vivax malariaWhat Is Known about the Immune Response Induced by Plasmodium vivax Malaria Vaccine Candidates?Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomesImmunomic approaches for antigen discovery of human parasites.Vaccines to Accelerate Malaria Elimination and Eventual Eradication.Proteogenomic analysis of the total and surface-exposed proteomes of Plasmodium vivax salivary gland sporozoites.Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development.Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria Parasite.Controlled Human Malaria Infection: Applications, Advances and Challenges.malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication.Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge.Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.The in Vitro Antigenicity of Plasmodium vivax Rhoptry Neck Protein 2 (PvRON2) B- and T-Epitopes Selected by HLA-DRB1 Binding Profile.Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral VectorsChimeric Plasmodium falciparum parasites expressing Plasmodium vivax circumsporozoite protein fail to produce salivary gland sporozoitesMalaria Vaccines: Recent Advances and New Horizons
P2860
Q28066456-CD004239-C60C-445A-9D41-ADEAEA46A932Q33572458-629D97EA-11F1-4D37-BB6C-F35467390FEDQ33798074-64F993EC-67FF-4C7E-86F8-E823F5166C46Q36215894-762211A3-C869-4336-A662-33B93FBE5090Q36247474-D0C3A916-DC85-49EB-810B-1CBA09D9061BQ37290599-46CF60D5-E48E-4EE0-8416-833DCB16C620Q37638131-97FD1F94-85B0-497E-A0F0-245AA3B3D1ABQ37696415-CF355900-D725-4BAD-9103-F038FC8CFBB1Q38989213-478BE43C-EBE3-470E-A5AA-CCF9A9E33D29Q39296506-3D41A8FD-B496-4E90-8DC8-4831E80B3B7AQ39501630-9092A4B8-C9ED-4252-9FE0-34996288D1AFQ41994105-FF866E57-D817-469B-A829-4983B1C6DBE8Q42699604-DB334F2B-1899-4078-92B9-D1554ABACFDAQ44168331-0E33C0F5-118F-4E5C-81D6-D405CA8320FCQ47134819-19880B7B-6E92-47A4-8CDD-996DC497B8E1Q48022505-E4306E07-A824-45C9-B090-5A8D2F616579Q52561260-D72160EF-9881-4006-896E-45D2BE9FA807Q55380572-C3A74EA2-46B1-4640-8CAD-03AC99277F2BQ56341814-723F2108-42B4-4AB4-8A26-A993203193BDQ56345472-4F0FFDDE-59EB-4B8C-8867-F302CD68DAC2Q56362064-95D7E4F8-E801-40DE-A370-7256E020FBC2
P2860
Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Phase 1/2a Trial of Plasmodium ...... Immunogenicity, and Efficacy.
@ast
Phase 1/2a Trial of Plasmodium ...... Immunogenicity, and Efficacy.
@en
type
label
Phase 1/2a Trial of Plasmodium ...... Immunogenicity, and Efficacy.
@ast
Phase 1/2a Trial of Plasmodium ...... Immunogenicity, and Efficacy.
@en
prefLabel
Phase 1/2a Trial of Plasmodium ...... Immunogenicity, and Efficacy.
@ast
Phase 1/2a Trial of Plasmodium ...... Immunogenicity, and Efficacy.
@en
P2093
P2860
P921
P1476
Phase 1/2a Trial of Plasmodium ...... Immunogenicity, and Efficacy.
@en
P2093
Anjali Yadava
Ashley Birkett
Christian F Ockenhouse
Cynthia Lee
Donna Tosh
Edwin Kamau
Falgunee Parekh
Jack Komisar
James F Cummings
Jason Regules
P2860
P304
P356
10.1371/JOURNAL.PNTD.0004423
P407
P577
2016-02-26T00:00:00Z